Key result
β-blocker use was not associated with increased all-cause mortality in a propensity-matched cohort of patients with pulmonary arterial hypertension (HR 1.2; 95% CI 0.8-2.0).
Why the study?
Does beta-blocker therapy increase all-cause mortality in patients with pulmonary arterial hypertension?
Cohort (n=564)
No
Does beta-blocker therapy increase all-cause mortality in patients with pulmonary arterial hypertension?
Hazard Ratio: 1.2 (95% CI 0.8–2)
p-value: p=0.71
Beta-blocker therapy does not appear to be associated with increased long-term mortality in patients with pulmonary arterial hypertension, suggesting they may be safe to use when otherwise indicated.
No takes yet. Share an insight, caveat, or question.
May support β-blocker use when indicated in PAH; leaves open need for randomized confirmation.
Thenappan et al. (2014) conducted a cohort in Pulmonary arterial hypertension (n=564). β-blocker therapy vs. No β-blocker therapy was evaluated on All-cause mortality (HR 1.2, 95% CI 0.8-2.0, p=0.71). β-blocker use was not associated with increased all-cause mortality in a propensity-matched cohort of patients with pulmonary arterial hypertension (HR 1.2; 95% CI 0.8-2.0).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: